# Noom's GLP-1 Program Combines Medication with Behavioral Support
Noom Med launched a new GLP-1 prescription program that pairs weight-loss medications with the company's behavioral coaching approach. The program, called GLP-1Rx, delivers clinically-backed treatment customized to individual needs.
GLP-1 receptor agonists like semaglutide and tirzepatide have transformed weight management in recent years. These medications work by regulating appetite hormones and improving blood sugar control. Research shows they produce significant weight loss when combined with lifestyle changes. However, medication alone isn't enough. People who use GLP-1s without addressing eating patterns and activity often regain weight when they stop the drug.
This is where Noom's model differs. The company integrates its behavior-change framework with medical supervision. Users receive prescriptions from licensed clinicians while accessing Noom's psychology-based app, which uses cognitive techniques to help people examine their relationships with food and build sustainable habits.
The program positions itself as a bridge between medication and lifestyle change. Rather than treating weight loss as purely a pharmaceutical problem, Noom's approach acknowledges that successful weight management requires both medical intervention and behavioral work. The "hype friend" framing suggests the program offers encouragement and accountability alongside prescriptions.
Noom's research team has published studies showing that their behavioral app improves outcomes in chronic disease management. The addition of GLP-1 prescriptions expands their offering beyond the app-only model they've offered since 2008. Telemedicine clinicians handle medication management while coaches provide ongoing support through the app.
This model addresses a real gap in weight-loss care. Many people receive GLP-1 prescriptions from their primary care doctors without comprehensive behavioral support. Others use telehealth services that provide prescriptions but no follow-